FDA saddles Orexigen with weighty data demand

One year's data is not enough. Orexigen Therapeutics has started laying off 40 percent of staff following FDA's override of an expert panel endorsement and rejection of its obesity treatment application. Additional cardiovascular data required could take two years and $200 million to collect. Story

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.